好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

FOSMN Syndrome Presenting with Bulbar Onset Preceding Trigeminal Sensory Loss
Neuromuscular and Clinical Neurophysiology (EMG)
P13 - Poster Session 13 (8:00 AM-9:00 AM)
10-010

To report an intriguing case of a patient with the rare Facial Onset Sensory and Motor Neuronopathy (FOSMN) syndrome who developed bulbar weakness prior to trigeminal sensory loss. 

FOSMN is a very rare neurodegenerative disease first described in 2006 and since then only 100 cases have been reported 1. The clinical course is characterized by an initial trigeminal sensory loss followed by bulbar dysfunction and progressive muscle weakness in a cranial to caudal pattern. FOSMN usually presents with a predominantly lower motor neuron pattern of weakness with a smaller proportion of patients also exhibiting upper motor neuron signs. There is only one prior reported case of bulbar symptoms preceding sensory symptoms 2. The pathophysiology remains unknown but it is postulated to be a TAR DNA-binding protein 43 (TDP-43) proteinopathy similar to amyotrophic lateral sclerosis and frontotemporal dementia1. It may in fact be immune mediated as a handful of cases have responded to IVIG therapy 3,4.

Literature review performed and case described.  

An otherwise healthy 65-year old female presented with a 12-month history of speech disturbance, dysphagia, tongue fasciculations, diffuse hyperreflexia and lower facial weakness without trigeminal sensory loss. Diagnostic studies including MRI-Brain, EMG and extensive autoantibody and neuropathy work-up were negative. Two months later she returned to clinic with numbness in the right V2 trigeminal distribution. Given the presence of trigeminal sensory loss in conjunction with facial onset progressive weakness, the patient was suspected to have FOSMN syndrome, with other differentials including progressive bulbar onset amyotrophic lateral sclerosis, however such prominent sensory symptoms would be unusual.

This case adds to the 100 documented FOSMN cases in the existing literature and illustrates a possible clinical course of FOSMN where bulbar weakness precedes trigeminal sensory loss. 

Authors/Disclosures
Adam Uppendahl, MD (Cedars-Sinai)
PRESENTER
Dr. Uppendahl has nothing to disclose.
Christina Tan, MD Dr. Tan has nothing to disclose.
Ron J. Danziger, MD (Cedars Sinai) Dr. Danziger has nothing to disclose.
Richard A. Lewis, MD, FAAN (Cedars-Sinai Medical Center) Dr. Lewis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Argenx. Dr. Lewis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for CSL Behring. Dr. Lewis has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Lewis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Grifols. Dr. Lewis has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Takeda. Dr. Lewis has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Nuvig. Dr. Lewis has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Dianthus. Dr. Lewis has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Janssen. Dr. Lewis has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Medscape. Dr. Lewis has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Annexon. Dr. Lewis has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Immunovant. Dr. Lewis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BioCryst. Dr. Lewis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NervoSave. Dr. Lewis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Annexon. Dr. Lewis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Lewis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Lewis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Immunovant. Dr. Lewis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TGTX. Dr. Lewis has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Boehringer-Ingleheim. Dr. Lewis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Intellia. Dr. Lewis has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Cartesian. Dr. Lewis has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for CME Outfitters. Dr. Lewis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PeerVision. Dr. Lewis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Up to Date. Dr. Lewis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Lewis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Boehringer Ingelheim. Dr. Lewis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. Dr. Lewis has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Lewis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Intellia. Dr. Lewis has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Shernoff et al. Dr. Lewis has received publishing royalties from a publication relating to health care.